Wechselwirkungen · Adtralza
Adtralza 150 mg solution for injection in pre-filled syringe Adtralza 300 mg solution for injection in pre-filled pen · Abschnitt 4.5 · PDF-Seite 5
HOS-145534 · Präparat HOS-099366
Immune responses to non-live vaccines were assessed in a study in which adult patients with atopic dermatitis were treated with an initial dose of 600 mg (four 150 mg injections) followed by 300 mg every second (other) week administered as subcutaneous injection. After 12 weeks of tralokinumab administration, patients were vaccinated with a combined tetanus, diphtheria, and acellular pertussis vaccine, and a meningococcal vaccine and immune responses were assessed 4 weeks later. Antibody responses to both tetanus vaccine and meningococcal vaccine were similar in tralokinumab-treated and placebo-treated patients. No adverse interactions between either of the non-live vaccines or tralokinumab were noted in the study. Therefore, patients receiving tralokinumab may receive concurrent inactivated or non-live vaccinations.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tralokinumab (HOS-145531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-28T11:56:00Z · SHA-256 83eaa444d96a4d6e69d81213cba4604bd7b5b4375717ab35b9ffffc1dd714534 · Passage 1dad459a0045b1be9cc39cb0f45784d3dd637b868ba534fc113a56a790f6b061 · Zeichen 120–948 im Abschnitt